Pfizer Gets Back to Growth

PFE Revenue (Annual) Chart

PFE Revenue (Annual) data by YCharts .

Turning a corner

In a bid to protect its profits, Pfizer embarked on a major restructuring to cut costs that included selling its nutrition business, and spinning off its animal health business. Those decisions have cut Pfizer's SG&A expenses from more than $19 billion to less than $15 billion. With the company forecast to deliver revenue growth again, the benefit of leveraging rising sales against lower costs should lead to higher profit in the coming years.

Assuming currency exchange rates remain similar to last year, Pfizer management believes that the company's revenue will improve to between $51.3 billion and $53.3 billion this year, and that its adjusted EPS will improve to between $2.36 and $2.46 in 2016, up from $2.20 in 2015. Pfizer owes this bullish forecast to a group of fast-growing drugs, and its $17 billion acquisition of the specialty drug company Hospira.

Sales of the pneumonia vaccine Prevnar 13 grew 102% year over year, and that helped lift total Prevnar family revenue to $6.245 billion. Sales of its rheumatoid arthritis drug, Xeljanz, climbed 70%, to $523 million, and collaboration revenue, which includes sales of the anticoagulant Eliquis, jumped 65%, to $1.25 billion. Pfizer also notched $723 million in sales of Ibrance last year -- not bad for its first year on the market.

Additionally, Pfizer added more than $4 billion in annual sales when it completed its acquisition of Hospira last September.

Source: Pfizer.

Looking ahead

Pfizer has 16 programs in registration or phase 3 studies, and its mid-stage pipeline includes a host of intriguing trials that could boost sales someday. Among the most intriguing of Pfizer's late-stage programs are avelumab, a cancer drug targeting non-small cell lung cancer, bococizumab, a cholesterol fighting PCSK9 inhibitor, and the type 2 diabetes drug ertugliflozin, which is being co-developed with Merck & Co. .

Pfizer also has an attractive late-stage pipeline of biosimilars that it got in the Hospira deal. That pipeline includes generic alternatives to multibillion dollar top sellers like Humira and Remicade, and puts Pfizer in a strong position to compete for market share in what it believes will be a $20 billion market by 2020.

The company's planned $160 billion merger with Botox-maker Allergan offers up even more pipeline opportunity because Allergan has 20 specialty drugs in mid- or late-stage development, including depression and schizophrenia drugs that could also become blockbusters.

Overall, Pfizer's return to growth this year, and its pipeline opportunities, suggest to me that Pfizer is about to enter a multi-year period of top- and bottom-line growth. If so, then it might be time to consider picking up its shares in portfolios.

The next billion-dollar iSecret

The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .

The article Pfizer Gets Back to Growth originally appeared on

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.